title: Management of non-clear cell renal cell carcinoma: Current approaches.
abstract: Non-clear cell renal cell carcinoma includes several histological variants. Tumor biology has significant effect on the duration of the disease. Prognosis at formally similar disease stages may differ despite same surgical treatment approaches to clear and non-clear cell renal cell carcinomas. Tumor sensitivity to pharmacotherapy also depends on the histological subtype. This article offers detailed discussion on current treatment options for patients with papillary, chromophobe, and other types of renal cell carcinoma.
authors.affiliation: Kidney Cancer Research Bureau, Russian Federation, Moscow, Russia. Electronic address: office@kidneytumor.org.
authors.forename: Ilya
authors.initials: I
authors.lastname: Tsimafeyeu
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D000068338:Everolimus / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D009392:Nephrectomy; D000077594:Nivolumab; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000077594:Nivolumab; C401859:temsirolimus; D000068338:Everolimus; D020123:Sirolimus
keywords: Classification; Non–clear cell renal cell carcinoma; Prognosis; Surgical treatment; Targeted therapy